

StemRIM Announces Patent Registration in China for Peripheral Peptides of the HMGB1 Fragment Peptide, Redasemtide

Osaka, Japan, August 8, 2024 – StemRIM Inc. (TSE:4599, President and CEO: Masatsune Okajima; “StemRIM” or “Company”) announces that a substance patent related to the peripheral peptides of "Regeneration-Inducing Medicine™" development candidate, Redasemtide, has been registered in China as detailed below.

Title of Invention : Peptides for Inducing Tissue Regeneration and Their Applications
Region : China
Application No. : 202111352869.9
Registration No. : To be determined
Applicant : StemRIM Inc.

This patent comprehensively covers the substance patent for the peripheral peptides, in addition to the substance patent for Redasemtide already obtained in China. With this patent, our company will hold rights not only to Redasemtide but also to similar substances that have or may have regenerative induction effects. This will prevent the development of generics and counterfeit products, thereby ensuring our development advantage in the Chinese market for "Regeneration-Inducing Medicine™".

As of 2024, the pharmaceutical market in China is the second largest in the world, and it is projected to reach a market size of \$185 billion to \$215 billion by 2028. Driven by economic growth and urbanization, the demand for new drugs is increasing, and further market expansion is anticipated. Against this backdrop, China represents a critical market, second only to the United States, which holds the largest market share globally. In this context, obtaining comprehensive development rights for the "Regeneration-Inducing Medicine™" Redasemtide and its peripheral peptides will broadly ensure the development potential of Redasemtide in the Chinese market. This will also provide an opportunity to promote the global expansion of "Regeneration-Inducing Medicine™".

The impact on the financial performance for the fiscal year ending July 31, 2025, is insignificant. We will promptly disclose any additional information that needs to be disclosed.

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged

or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with extrapulmonary mesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.

Management & Administrator Dept.

E-Mail: stemrim-ir@stemrim.com

Twitter: [@StemRIM_Inc](https://twitter.com/StemRIM_Inc)

For more information, please visit the StemRIM website (<https://stemrim.com/english/>)